Abeona Therapeutics Inc. [NASDAQ: ABEO] price surged by 11.93 percent to reach at $0.13.
A sum of 5966795 shares traded at recent session while its average daily volume was at 1.41M shares. Abeona Therapeutics Inc. shares reached a high of $1.27 and dropped to a low of $1.11 until finishing in the latest session at $1.22.
The average equity rating for ABEO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Abeona Therapeutics Inc. [ABEO]:
B. Riley FBR have made an estimate for Abeona Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 18, 2020. While these analysts kept the previous recommendation, SVB Leerink raised their target price to Outperform. The new note on the price target was released on February 10, 2020, representing the official price target for Abeona Therapeutics Inc. stock. Previously, the target price had yet another raise from $2 to $4, while Cantor Fitzgerald kept a Neutral rating on ABEO stock.
The Average True Range (ATR) for Abeona Therapeutics Inc. is set at 0.18 The Price to Book ratio for the last quarter was 0.94, with the Price to Cash per share for the same quarter was set at 1.27.
ABEO Stock Performance Analysis:
Abeona Therapeutics Inc. [ABEO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.91. With this latest performance, ABEO shares dropped by -38.38% in over the last four-week period, additionally sinking by -46.96% over the last 6 months – not to mention a drop of -48.74% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABEO stock in for the last two-week period is set at 30.94, with the RSI for the last a single of trading hit 33.45, and the three-weeks RSI is set at 31.90 for Abeona Therapeutics Inc. [ABEO]. The present Moving Average for the last 50 days of trading for this stock 2.2260, while it was recorded at 1.0860 for the last single week of trading, and 2.6487 for the last 200 days.
Insight into Abeona Therapeutics Inc. Fundamentals:
Return on Total Capital for ABEO is now -48.12, given the latest momentum, and Return on Invested Capital for the company is -47.87. Return on Equity for this stock declined to -48.82, with Return on Assets sitting at -38.35. When it comes to the capital structure of this company, Abeona Therapeutics Inc. [ABEO] has a Total Debt to Total Equity ratio set at 4.46. Additionally, ABEO Total Debt to Total Capital is recorded at 4.27, with Total Debt to Total Assets ending up at 3.56. Long-Term Debt to Equity for the company is recorded at 3.50, with the Long-Term Debt to Total Capital now at 3.35.
Reflecting on the efficiency of the workforce at the company, Abeona Therapeutics Inc. [ABEO] managed to generate an average of -$866,841 per employee.Abeona Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.90 and a Current Ratio set at 2.90.
ABEO Stock EPS
With the latest financial reports released by the company, Abeona Therapeutics Inc. posted -0.35/share EPS, while the average EPS was predicted by analysts to be reported at -0.44/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 20.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABEO.
Abeona Therapeutics Inc. [ABEO] Insider Position Details
There are presently around $53 million, or 53.20% of ABEO stock, in the hands of institutional investors. The top three institutional holders of ABEO stocks are: GREAT POINT PARTNERS I LP with ownership of 7,213,012, which is approximately 0% of the company’s market cap and around 1.70% of the total institutional ownership; ADAGE CAPITAL PARTNERS GP, L.L.C., holding 5,500,000 shares of the stock with an approximate value of $6.71 million in ABEO stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $5.52 million in ABEO stock with ownership of nearly -16.945% of the company’s market capitalization.
Positions in Abeona Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 48 institutional holders increased their position in Abeona Therapeutics Inc. [NASDAQ:ABEO] by around 3,022,909 shares. Additionally, 32 investors decreased positions by around 3,942,910 shares, while 18 investors held positions by with 36,575,557 shares. The mentioned changes placed institutional holdings at 43,541,376 shares, according to the latest SEC report filing. ABEO stock had 13 new institutional investments in for a total of 516,487 shares, while 11 institutional investors sold positions of 1,863,852 shares during the same period.